Umbilical cord blood (UCB) banking has become a new medical strength. It offers gravid parents a biological insurance policy that can be used in the event of a child or family member's life-grievous illness and puts patients in a position of control over their own treatment options. Still, its graduation to stuffy therapy in the clinical sphere trusts on breakthrough research that will prove its effective for a range of disorders. Booming the multipurpose cells found within the mono nuclear rational of Umbilical cord blood so that capable medication can be attained, abolishing its safety and limitations in HLA- mismatched acquirers, process its executions of action, and proving its substitute in a broad assortment of both rare and common illnesses and diseases are a few of the challenges left to gear. Yet, the tract is moving fast and new UCB- based therapies are on the skyline.